lung cancer
Conditions
Interventions
CBDCA+TS-1
Sponsors
Teikyo University School of Medicine
Saitama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Cases which have been diagnosed with non-small cell lung cancer pathologically. Low malignant potential tumors and large-cell neuroendocrine carcinoma such as cartinoid tumor, mucoepidermoid carcinoma and adenoid cystic carcinoma are excluded. 2) Cases which are at pathological stages II and IIIA 3) Cases in which complete removal of a tumor has been confirmed pathologically by a surgeon. 4) Cases in which surgical resection including lobectomy or more has been performed. Cases which have undergone bronchoplasty are included. 5) Cases in which hilar and mediastinal lymph node dissection have been performed. 6) Cases in which no treatments excluding surgical treatments have been performed. 7) Cases with the performance status of between 0 and 1. 8) Cases older than 75 years old. 9) Cases indicating following organ (bone marrow, liver, kidney and lung) functions 10) Cases in which chemotherapy can be initiated within 10 weeks after surgery 11) Cases in which a consent form for participating the study has been signed by a patient.
Exclusion criteria
Exclusion criteria: 1) Cases in which patients have not been recovered from a complication after surgery 2) Cases in which active infections such as bacterial infections have occurred. 3) Cases in which the presence of pulmonary fibrosis or interstitial pneumonia (pathologically active interstitial pneumonia after surgery) has been confirmed. 4) Cases in which myocardial infarction occurred within the last 6 months 5) Cases with complications which are hard to control (such as cardiac disease, liver disease, severe diabetes and hemorrhage). 6) Cases with peripheral neuropathy of above Grade 2 7) Cases with active double cancer (synchronous double cancer and metachronous double cancer with 5 years of disease-free period). 8) Cases during flucytosine treatment (the co-administration of TS-1 is prohibited). 9) Other cases in which a primary physician considered not to be suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment completion rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival period (OS), Recurrence free survival period (RFS), Adverse effect occurrence rate, recurrence pattern | — |
Countries
Japan
Contacts
Public ContactNoriyuki Matsutani
Teikyo University School of Medicine Surgery
Outcome results
None listed